<?xml version="1.0"?>
<presentation title="09 Chang Min Cho" width="720.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="59.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2010" type="compound" hasExternalAudio="0" uid="{28419F46-3FBD-4662-94DD-B898A7B6A7CB}">
	<presenters>
		<presenter name="Chang Min Cho" title="Kyungpook National University" email="" web="" phone="" photoAssetId="">
			<bio>Contrast-enhanced EUS for Pancreatic Lesion</bio>
		</presenter>
	</presenters>
	<references/>
	<soundAssets>
		<soundAsset id="sndAsset0" src="sound1.mp3" embedded="0" size="397942" duration="14211"/>
		<soundAsset id="sndAsset1" src="sound2.mp3" embedded="0" size="145599" duration="5198"/>
		<soundAsset id="sndAsset2" src="sound3.mp3" embedded="0" size="987474" duration="35265"/>
		<soundAsset id="sndAsset3" src="sound4.mp3" embedded="0" size="1191542" duration="42553"/>
		<soundAsset id="sndAsset4" src="sound5.mp3" embedded="0" size="1024045" duration="36571"/>
		<soundAsset id="sndAsset5" src="sound6.mp3" embedded="0" size="248731" duration="8882"/>
		<soundAsset id="sndAsset6" src="sound7.mp3" embedded="0" size="1146925" duration="40960"/>
		<soundAsset id="sndAsset7" src="sound8.mp3" embedded="0" size="1609919" duration="57496"/>
		<soundAsset id="sndAsset8" src="sound9.mp3" embedded="0" size="546422" duration="19513"/>
		<soundAsset id="sndAsset9" src="sound10.mp3" embedded="0" size="1414628" duration="50521"/>
		<soundAsset id="sndAsset10" src="sound11.mp3" embedded="0" size="874834" duration="31242"/>
		<soundAsset id="sndAsset11" src="sound12.mp3" embedded="0" size="1342948" duration="47961"/>
		<soundAsset id="sndAsset12" src="sound13.mp3" embedded="0" size="1444616" duration="51592"/>
		<soundAsset id="sndAsset13" src="sound14.mp3" embedded="0" size="1174719" duration="41953"/>
		<soundAsset id="sndAsset14" src="sound15.mp3" embedded="0" size="1238354" duration="44225"/>
		<soundAsset id="sndAsset15" src="sound16.mp3" embedded="0" size="686856" duration="24529"/>
		<soundAsset id="sndAsset16" src="sound17.mp3" embedded="0" size="525942" duration="18782"/>
		<soundAsset id="sndAsset17" src="sound18.mp3" embedded="0" size="616639" duration="22021"/>
		<soundAsset id="sndAsset18" src="sound19.mp3" embedded="0" size="792182" duration="28291"/>
		<soundAsset id="sndAsset19" src="sound20.mp3" embedded="0" size="581531" duration="20767"/>
		<soundAsset id="sndAsset20" src="sound21.mp3" embedded="0" size="905554" duration="32340"/>
		<soundAsset id="sndAsset21" src="sound22.mp3" embedded="0" size="451336" duration="16118"/>
		<soundAsset id="sndAsset22" src="sound23.mp3" embedded="0" size="2000502" duration="71445"/>
		<soundAsset id="sndAsset23" src="sound24.mp3" embedded="0" size="921645" duration="32914"/>
		<soundAsset id="sndAsset24" src="sound25.mp3" embedded="0" size="1289554" duration="46054"/>
		<soundAsset id="sndAsset25" src="sound26.mp3" embedded="0" size="896776" duration="32026"/>
		<soundAsset id="sndAsset26" src="sound27.mp3" embedded="0" size="244342" duration="8725"/>
		<soundAsset id="sndAsset27" src="sound28.mp3" embedded="0" size="602742" duration="21525"/>
		<soundAsset id="sndAsset28" src="sound29.mp3" embedded="0" size="1748891" duration="62459"/>
		<soundAsset id="sndAsset29" src="sound30.mp3" embedded="0" size="335771" duration="11990"/>
		<soundAsset id="sndAsset30" src="sound31.mp3" embedded="0" size="795839" duration="28421"/>
		<soundAsset id="sndAsset31" src="sound32.mp3" embedded="0" size="328456" duration="11729"/>
		<soundAsset id="sndAsset32" src="sound33.mp3" embedded="0" size="208502" duration="7445"/>
		<soundAsset id="sndAsset33" src="sound34.mp3" embedded="0" size="718308" duration="25652"/>
		<soundAsset id="sndAsset34" src="sound35.mp3" embedded="0" size="114879" duration="4101"/>
	</soundAssets>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
		<graphicAsset id="imgAsset18" src="thmb19.swf" embedded="0"/>
		<graphicAsset id="imgAsset19" src="thmb20.swf" embedded="0"/>
		<graphicAsset id="imgAsset20" src="thmb21.swf" embedded="0"/>
		<graphicAsset id="imgAsset21" src="thmb22.swf" embedded="0"/>
		<graphicAsset id="imgAsset22" src="thmb23.swf" embedded="0"/>
		<graphicAsset id="imgAsset23" src="thmb24.swf" embedded="0"/>
		<graphicAsset id="imgAsset24" src="thmb25.swf" embedded="0"/>
		<graphicAsset id="imgAsset25" src="thmb26.swf" embedded="0"/>
		<graphicAsset id="imgAsset26" src="thmb27.swf" embedded="0"/>
		<graphicAsset id="imgAsset27" src="thmb28.swf" embedded="0"/>
		<graphicAsset id="imgAsset28" src="thmb29.swf" embedded="0"/>
		<graphicAsset id="imgAsset29" src="thmb30.swf" embedded="0"/>
		<graphicAsset id="imgAsset30" src="thmb31.swf" embedded="0"/>
		<graphicAsset id="imgAsset31" src="thmb32.swf" embedded="0"/>
		<graphicAsset id="imgAsset32" src="thmb33.swf" embedded="0"/>
		<graphicAsset id="imgAsset33" src="thmb34.swf" embedded="0"/>
		<graphicAsset id="imgAsset34" src="thmb35.swf" embedded="0"/>
	</graphicAssets>
	<playlists/>
	<narration>
		<audioTracks>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset0">
				<startTimestamp slideIndex="0" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="0" stepIndex="0" timeOffset="14.1809998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset1">
				<startTimestamp slideIndex="1" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="1" stepIndex="0" timeOffset="5.1719999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset2">
				<startTimestamp slideIndex="2" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="2" stepIndex="0" timeOffset="35.2350000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset3">
				<startTimestamp slideIndex="3" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="3" stepIndex="0" timeOffset="42.5089989"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset4">
				<startTimestamp slideIndex="4" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="4" stepIndex="0" timeOffset="36.5369987"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset5">
				<startTimestamp slideIndex="5" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="5" stepIndex="0" timeOffset="8.8420000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset6">
				<startTimestamp slideIndex="6" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="6" stepIndex="0" timeOffset="40.9080000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset7">
				<startTimestamp slideIndex="7" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="7" stepIndex="0" timeOffset="57.4570000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset8">
				<startTimestamp slideIndex="8" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="8" stepIndex="0" timeOffset="19.4860000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset9">
				<startTimestamp slideIndex="9" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="9" stepIndex="0" timeOffset="50.4840000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset10">
				<startTimestamp slideIndex="10" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="10" stepIndex="0" timeOffset="31.1980000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset11">
				<startTimestamp slideIndex="11" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="11" stepIndex="0" timeOffset="47.9150000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset12">
				<startTimestamp slideIndex="12" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="12" stepIndex="0" timeOffset="51.5509987"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset13">
				<startTimestamp slideIndex="13" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="13" stepIndex="0" timeOffset="41.9090000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset14">
				<startTimestamp slideIndex="14" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="14" stepIndex="0" timeOffset="44.1770000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset15">
				<startTimestamp slideIndex="15" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="15" stepIndex="0" timeOffset="24.4899998"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset16">
				<startTimestamp slideIndex="16" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="16" stepIndex="0" timeOffset="18.7520000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset17">
				<startTimestamp slideIndex="17" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="17" stepIndex="0" timeOffset="21.9890000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset18">
				<startTimestamp slideIndex="18" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="18" stepIndex="0" timeOffset="28.2619991"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset19">
				<startTimestamp slideIndex="19" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="19" stepIndex="0" timeOffset="20.7199993"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset20">
				<startTimestamp slideIndex="20" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="20" stepIndex="0" timeOffset="32.2990000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset21">
				<startTimestamp slideIndex="21" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="21" stepIndex="0" timeOffset="16.0799999"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset22">
				<startTimestamp slideIndex="22" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="22" stepIndex="0" timeOffset="71.4049988"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset23">
				<startTimestamp slideIndex="23" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="23" stepIndex="0" timeOffset="32.8660000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset24">
				<startTimestamp slideIndex="24" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="24" stepIndex="0" timeOffset="46.0130000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset25">
				<startTimestamp slideIndex="25" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="25" stepIndex="0" timeOffset="31.9990000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset26">
				<startTimestamp slideIndex="26" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="26" stepIndex="0" timeOffset="8.6750000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset27">
				<startTimestamp slideIndex="27" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="27" stepIndex="0" timeOffset="21.4880000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset28">
				<startTimestamp slideIndex="28" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="28" stepIndex="0" timeOffset="62.4290000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset29">
				<startTimestamp slideIndex="29" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="29" stepIndex="0" timeOffset="11.9399996"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset30">
				<startTimestamp slideIndex="30" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="30" stepIndex="0" timeOffset="28.3950000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset31">
				<startTimestamp slideIndex="31" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="31" stepIndex="0" timeOffset="11.6780000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset32">
				<startTimestamp slideIndex="32" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="32" stepIndex="0" timeOffset="7.4070000"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset33">
				<startTimestamp slideIndex="33" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="33" stepIndex="0" timeOffset="25.6259995"/>
			</audioTrack>
			<audioTrack volume="1.0000000" soundAssetId="sndAsset34">
				<startTimestamp slideIndex="34" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="34" stepIndex="0" timeOffset="4.0710000"/>
			</audioTrack>
		</audioTracks>
	</narration>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>true</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>true</visible>
				<buttons>
					<button type="attachments" visible="false"/>
					<button type="presenterInfo" visible="false"/>
					<button type="markerTools" visible="true"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>true</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>true</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>true</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>true</showPresenterInfo>
				<showPresenterVideo>false</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>false</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="always"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="Contrast-enhanced EUS for Pancreatic Lesion" titleNormalized="contrast-enhanced eus for pancreatic lesion" src="slide1.swf" size="1772" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="14.1799998"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Contrast-enhanced EUS for Pancreatic Lesion
Kyungpook National University Medical Center
Center for Hepatobiliary and Pancreatic Tumors
Chang Min Cho
2016-09-09 Session 3. Advances in Diagnosis and Management of Solid Pancreatic Tumor</text>
		</slide>
		<slide index="1" title="Index" titleNormalized="index" src="slide2.swf" size="1847" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="5.1709999"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Index
Introduction
History of CE-US and CE-EUS
Classification of USAs
CE-EUS and CH-EUS
Clinical applications of EUS using UCAs
Quantitative analysis of CH-EUS
Take home messages</text>
		</slide>
		<slide index="2" title="Progress of EUS" titleNormalized="progress of eus" src="slide3.swf" size="3784" advanceOnTime="1" framesCount="626" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="625" playTime="26.0416667" pauseTime="9.1983350"/>
			</animationSteps>
			<notes>Recently, much effort has been put to further improve the sensitivity, specificity and overall accuracy of EUS.
One of the major advances is the utilization of contrast agents for better delineation of the vascularity and tissue perfusion of the target lesion.
최근까지, 초음파 내시경 기기에 있어 많은 발전이 있어왔다.</notes>
			<notesNormalized>recently, much effort has been put to further improve the sensitivity, specificity and overall accuracy of eus.
one of the major advances is the utilization of contrast agents for better delineation of the vascularity and tissue perfusion of the target lesion.
최근까지, 초음파 내시경 기기에 있어 많은 발전이 있어왔다.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Recently, much effort has been put to further improve the sensitivity, specificity and overall accuracy of EUS.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;One of the major advances is the utilization of contrast agents for better delineation of the vascularity and tissue perfusion of the target lesion.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;최근까지, 초음파 내시경 기기에 있어 많은 발전이 있어왔다.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Progress of EUS
Mechanical radial scanning method
Electronic scanning method
Radial scanning
Linear scanning
Improvement of B-mode image quality
Color/power Doppler image
Harmonic image
2. Utilization of application
CE-EUS and CH-EUS
3-D imaging
Real time tissue elastography
EUS-tissue sampling
Histology/cytology
Gene expression analysis
2. Therapeutics
Drainage
Anti-cancer therapy</text>
		</slide>
		<slide index="3" title="EUS in pancreatic disease" titleNormalized="eus in pancreatic disease" src="slide4.swf" size="2261" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="42.5079989"/>
			</animationSteps>
			<notes>As you know, endoscopic ultrasound (EUS) has been an important imaging modality in the diagnosis of pancreatic diseases. Previous studies revealed that high sensitivity for the detection of small pancreatic lesions comparing to CT and MRI. Also, we can perform additional EUS-guided procedures: EUS-guided tissue sampling for cytopathologic diagnosis of benign or malignant disorders, EUS-guided celiac plexus block or neurolysis for pancreatic origin pain control, and cystic ablation for selected pancreatic cystic neoplasms. However, it has difficulty in the discrimination of solid pancreatic mass in the case of underlying chronic pancreatitis, that showed low specificity.</notes>
			<notesNormalized>as you know, endoscopic ultrasound (eus) has been an important imaging modality in the diagnosis of pancreatic diseases. previous studies revealed that high sensitivity for the detection of small pancreatic lesions comparing to ct and mri. also, we can perform additional eus-guided procedures: eus-guided tissue sampling for cytopathologic diagnosis of benign or malignant disorders, eus-guided celiac plexus block or neurolysis for pancreatic origin pain control, and cystic ablation for selected pancreatic cystic neoplasms. however, it has difficulty in the discrimination of solid pancreatic mass in the case of underlying chronic pancreatitis, that showed low specificity.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;As you know, endoscopic ultrasound (EUS) has been an important imaging modality in the diagnosis of pancreatic diseases. Previous studies revealed that high sensitivity for the detection of small pancreatic lesions comparing to CT and MRI. Also, we can perform additional EUS-guided procedures: EUS-guided tissue sampling for cytopathologic diagnosis of benign or malignant disorders, EUS-guided celiac plexus block or neurolysis for pancreatic origin pain control, and cystic ablation for selected pancreatic cystic neoplasms. However, it has difficulty in the discrimination of solid pancreatic mass in the case of underlying chronic pancreatitis, that showed low specificity.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS in pancreatic disease
Good diagnostic imaging modality
High sensitivity for detection of small lesions
Superior to CT and MRI in mass detection
Additional procedure
EUS-tissue sampling
EUS-CPB/CPN
EUS-ablation

Difficult in the discrimination of pancreatic mass in case of underlying chronic pancreatitis
Specificity: 33-75%
Wiersema MJ et al. Pancreatology (2001)
Bhutani MS et al. Endoscopy (2004)</text>
		</slide>
		<slide index="4" title="Ultrasound contrast agents (UCAs)" titleNormalized="ultrasound contrast agents (ucas)" src="slide5.swf" size="58338" advanceOnTime="1" framesCount="344" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="343" playTime="14.2916667" pauseTime="22.2453321"/>
			</animationSteps>
			<notes>UCAs are gas-containing microbubbles encapsulated in a resistance shell. This shell decreases dissolution or disruption of the microbubbles in the blood stream. When hit by an ultrasonic wave, the microbubbles would oscillate and generate an acoustic signal that would be detected and reproduced on an ultrasound image.</notes>
			<notesNormalized>ucas are gas-containing microbubbles encapsulated in a resistance shell. this shell decreases dissolution or disruption of the microbubbles in the blood stream. when hit by an ultrasonic wave, the microbubbles would oscillate and generate an acoustic signal that would be detected and reproduced on an ultrasound image.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;UCAs are gas-containing microbubbles encapsulated in a resistance shell. This shell decreases dissolution or disruption of the microbubbles in the blood stream. When hit by an ultrasonic wave, the microbubbles would oscillate and generate an acoustic signal that would be detected and reproduced on an ultrasound image.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ultrasound contrast agents (UCAs)
Composition
Inner microbubbles: air or heavy gases (perfluorocarbon or nitrogen)
Outer shell: albumin, lipid or polymerase
Clinical applications
Essential along with B-mode imaging in transabdominal USG
Particular for the differential diagnosis of solid liver lesions
Could replace liver biopsy for diagnosis of HCC
Piscaglia et al. Ultraschall Med (2012)
Dietrich CF. Ultraschall Med (2008)</text>
		</slide>
		<slide index="5" title="" titleNormalized="" src="slide6.swf" size="67173" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.8410000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
		</slide>
		<slide index="6" title="History of contrast enhanced US" titleNormalized="history of contrast enhanced us" src="slide7.swf" size="138408" advanceOnTime="1" framesCount="1902" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video0" videoClipId="ispring.resources_19825110.spr0_15125810" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_19825110.spr2_15125810" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video1" videoClipId="ispring.resources_19824b60.spr0_15131316" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_19824b60.spr2_15131316" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video2" videoClipId="ispring.resources_19825110.spr0_15140552" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_19825110.spr2_15140552" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video0" startPos="0.0000000"/>
				<playVideo frameIndex="0" videoId="video1" startPos="0.0000000"/>
				<playVideo frameIndex="0" videoId="video2" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="1901" playTime="40.9080009" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>History of contrast enhanced US
Matsuda and Yabuuchi (1986)
Carbon dioxide as a contrast agent
Evaluation of hepatic tumor
Pattern of parenchymal perfusion
Differentiation between in malignant and benign lesions in the liver
Organ specific vascularity (portal vein/sinusoidal)
HCC
Hemangioma
Metastasis</text>
		</slide>
		<slide index="7" title="History of CE-EUS" titleNormalized="history of ce-eus" src="slide8.swf" size="2322" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="57.4560007"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>History of CE-EUS
First reported by Kato et al (1995)
Fundamental EUS with CO2 gas
Angiographic intervention
Infusion of gas through a catheter implanted into celiac or superior mesenteric artery
Color and/or power Doppler equipment
Detection of direction of blood flow in large vessels
Poor sensitivity in detection of micro-vessel
Slow blood flow
Poor depiction for parenchymal perfusion

Kato T et al, Acta Radiol (1995)</text>
		</slide>
		<slide index="8" title="CE-EUS" titleNormalized="ce-eus" src="slide9.swf" size="1700" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="19.4850001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>CE-EUS
To improve the characterization of the vasculature inside the organ of interest
To better delineate benign from malignant pathology
To aid in staging and directing therapeutic procedures</text>
		</slide>
		<slide index="9" title="Ultrasound contrast agents (UCAs)" titleNormalized="ultrasound contrast agents (ucas)" src="slide10.swf" size="198382" advanceOnTime="1" framesCount="148" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="147" playTime="6.1250000" pauseTime="44.3590012"/>
			</animationSteps>
			<notes>Current UCAs consist of microbubbles with a 2-5 micron diameter capable of transpulmonary passage for systemic enhancement after intravenous injection. A bubble of this size is unstable in an aqueous system, and therefore, it must be encapsulated by a stabilizing shell to achieve long lasting persistence. The type of gas and the composition of the shell confer different physicochemical properties and different behaviours in the ultrasound field. However, the physical principles of the interaction between the microbubble and the incident ultrasound wave are basically the same.
First generation agents are microbubbles filled with air, but they generally require high acoustic power to produce oscillation or break its microbubbles. Second generation agents, including the commonly used SonoVueTM and SonazoidTM, are composed of gases that are less soluble and less likely to leak out from microbubbles, thereby lasting longer in the circulation. These agents can be oscillated or broken by lower acoustic power, and thus are more suitable for EUS because of the limited acoustic power produced by the small transducer. Third generation agents (EchogenTM) are capable of phase shifting from liquid to gas form once they reach body temperature.</notes>
			<notesNormalized>current ucas consist of microbubbles with a 2-5 micron diameter capable of transpulmonary passage for systemic enhancement after intravenous injection. a bubble of this size is unstable in an aqueous system, and therefore, it must be encapsulated by a stabilizing shell to achieve long lasting persistence. the type of gas and the composition of the shell confer different physicochemical properties and different behaviours in the ultrasound field. however, the physical principles of the interaction between the microbubble and the incident ultrasound wave are basically the same.
first generation agents are microbubbles filled with air, but they generally require high acoustic power to produce oscillation or break its microbubbles. second generation agents, including the commonly used sonovuetm and sonazoidtm, are composed of gases that are less soluble and less likely to leak out from microbubbles, thereby lasting longer in the circulation. these agents can be oscillated or broken by lower acoustic power, and thus are more suitable for eus because of the limited acoustic power produced by the small transducer. third generation agents (echogentm) are capable of phase shifting from liquid to gas form once they reach body temperature.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Current UCAs consist of microbubbles with a 2-5 micron diameter capable of transpulmonary passage for systemic enhancement after intravenous injection. A bubble of this size is unstable in an aqueous system, and therefore, it must be encapsulated by a stabilizing shell to achieve long lasting persistence. The type of gas and the composition of the shell confer different physicochemical properties and different behaviours in the ultrasound field. However, the physical principles of the interaction between the microbubble and the incident ultrasound wave are basically the same.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;First generation agents are microbubbles filled with air, but they generally require high acoustic power to produce oscillation or break its microbubbles. Second generation agents, including the commonly used SonoVueTM and SonazoidTM, are composed of gases that are less soluble and less likely to leak out from microbubbles, thereby lasting longer in the circulation. These agents can be oscillated or broken by lower acoustic power, and thus are more suitable for EUS because of the limited acoustic power produced by the small transducer. Third generation agents (EchogenTM) are capable of phase shifting from liquid to gas form once they reach body temperature.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ultrasound contrast agents (UCAs)










Gas containing microbubbles encased in a resistant shell
Oscillate when hit by an ultrasound wave to produce an acoustic ‘enhancement’ signal
Categorized by capability for transpulmonary passage and half-life
Relatively safe and no report of serious adverse event
Perfusion after UCAs injection
Micro-vessels
Parenchymal perfusion
Reddy NK et al. World J Gast (2011)</text>
		</slide>
		<slide index="10" title="Ultrasound contrast agents (UCAs)" titleNormalized="ultrasound contrast agents (ucas)" src="slide11.swf" size="2062" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="31.1970000"/>
			</animationSteps>
			<notes>After intravenous contrast injection, sonographic assessment of the target of interest could be performed by two methods: contrast enhanced color/power Doppler imaging (CED-EUS) and contrast enhanced harmonic imaging (CEH-EUS).</notes>
			<notesNormalized>after intravenous contrast injection, sonographic assessment of the target of interest could be performed by two methods: contrast enhanced color/power doppler imaging (ced-eus) and contrast enhanced harmonic imaging (ceh-eus).</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;After intravenous contrast injection, sonographic assessment of the target of interest could be performed by two methods: contrast enhanced color/power Doppler imaging (CED-EUS) and contrast enhanced harmonic imaging (CEH-EUS).&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ultrasound contrast agents (UCAs)
Images for vascularity and vessel pattern
Small volume and slow velocity blood flow
Principle of UCAs
Creation of multiple small interfaces with high echogenicity
Microbubbles: good backscatters and effectively reflecting US waves


Contrast-enhanced EUS
Color/power Doppler image (CED-EUS)
Harmonic image (CEH-EUS)</text>
		</slide>
		<slide index="11" title="CE-EUS" titleNormalized="ce-eus" src="slide12.swf" size="172808" advanceOnTime="1" framesCount="1033" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video3" videoClipId="ispring.resources_1d2813f0.spr0_15144046" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d2813f0.spr2_15144046" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="917" videoId="video3" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="1032" playTime="43.0000000" pauseTime="4.9150009"/>
			</animationSteps>
			<notes>Contrast agents were used initially as Doppler signal enhancer, including in contrast-enhanced EUS examinations (CE-EUS). Both color Doppler and power Doppler can be used, especially for regions with very low flow volumes, where the unenhanced signal is too weak or the signal-noise ratio is too poor. Although the contrast agent selectively enhances the useful signal to the detriment of the noise, the main disadvantage of these technique is the presence of artifacts; both tissue motion (flash) artifacts and blooming artifacts appear and impede the examinations. Flash artifacts are specific to the Doppler mode, appearing as color signals caused by tissue motion, being most commonly seen in hypoechoic areas, induced by cardiac or respiratory motion. Blooming artifacts appear as a consequence of the high amplification of the backscattered signal, which saturates the receiver and causes smearing of the color signal. They appear immediately after the wash-in phase and disappear when the concentration of contrast is lower.</notes>
			<notesNormalized>contrast agents were used initially as doppler signal enhancer, including in contrast-enhanced eus examinations (ce-eus). both color doppler and power doppler can be used, especially for regions with very low flow volumes, where the unenhanced signal is too weak or the signal-noise ratio is too poor. although the contrast agent selectively enhances the useful signal to the detriment of the noise, the main disadvantage of these technique is the presence of artifacts; both tissue motion (flash) artifacts and blooming artifacts appear and impede the examinations. flash artifacts are specific to the doppler mode, appearing as color signals caused by tissue motion, being most commonly seen in hypoechoic areas, induced by cardiac or respiratory motion. blooming artifacts appear as a consequence of the high amplification of the backscattered signal, which saturates the receiver and causes smearing of the color signal. they appear immediately after the wash-in phase and disappear when the concentration of contrast is lower.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Contrast agents were used initially as Doppler signal enhancer, including in contrast-enhanced EUS examinations (CE-EUS). Both color Doppler and power Doppler can be used, especially for regions with very low flow volumes, where the unenhanced signal is too weak or the signal-noise ratio is too poor. Although the contrast agent selectively enhances the useful signal to the detriment of the noise, the main disadvantage of these technique is the presence of artifacts; both tissue motion (flash) artifacts and blooming artifacts appear and impede the examinations. Flash artifacts are specific to the Doppler mode, appearing as color signals caused by tissue motion, being most commonly seen in hypoechoic areas, induced by cardiac or respiratory motion. Blooming artifacts appear as a consequence of the high amplification of the backscattered signal, which saturates the receiver and causes smearing of the color signal. They appear immediately after the wash-in phase and disappear when the concentration of contrast is lower.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>CE-EUS
Color and/or power Doppler image
Useful for evaluating large blood vessels with fast blood flow
UCAs: used as Doppler signal enhancer
For regions with very low flow volumes


Artifacts
Motion (flash)
Caused by tissue motion
Induced by cardiac or respiratory motion
Blooming
High amplification of backscattered signal
Over-painting</text>
		</slide>
		<slide index="12" title="Contrast-enhanced harmonic EUS" titleNormalized="contrast-enhanced harmonic eus" src="slide13.swf" size="79906" advanceOnTime="1" framesCount="2201" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video4" videoClipId="ispring.resources_1d282360.spr0_15152470" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d282360.spr2_15152470" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="1472" videoId="video4" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="2200" playTime="51.5509987" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>CEH-EUS was recently developed to overcome the difficulties experienced with Doppler EUS.
The past decade has witnessed great activity towards the development of stabilised microbubble contrast agents. During the same time period, there have also been enhancements of the available ultrasound equipment, such as HI-specific software and broad-band transducers, which have dramatically improved the ability of US to explore microcirculation and given rise to the evolution of contrast-enhanced transabdominal US for uses ranging from vascular imaging to images of the perfused tissue. Additionally, endoscopic ultrasonography (EUS) has become the imaging modality with the highest spatial resolution since its introduction in the 1980s. However, because of its low acoustic power and limited bandwidth, contrast-enhanced harmonic endoscopic ultrasound (CHEUS) has not been feasible until five years ago, when technological advances made contrast harmonic technology available for the first time for EUS. Although experience is still limited, several reports have highlighted this technique as a promising noninvasive method, not only for characterising lesions but also for better assessing tumour staging and resectability. In this article, we aim to review the physical principles of contrast harmonic imaging</notes>
			<notesNormalized>ceh-eus was recently developed to overcome the difficulties experienced with doppler eus.
the past decade has witnessed great activity towards the development of stabilised microbubble contrast agents. during the same time period, there have also been enhancements of the available ultrasound equipment, such as hi-specific software and broad-band transducers, which have dramatically improved the ability of us to explore microcirculation and given rise to the evolution of contrast-enhanced transabdominal us for uses ranging from vascular imaging to images of the perfused tissue. additionally, endoscopic ultrasonography (eus) has become the imaging modality with the highest spatial resolution since its introduction in the 1980s. however, because of its low acoustic power and limited bandwidth, contrast-enhanced harmonic endoscopic ultrasound (cheus) has not been feasible until five years ago, when technological advances made contrast harmonic technology available for the first time for eus. although experience is still limited, several reports have highlighted this technique as a promising noninvasive method, not only for characterising lesions but also for better assessing tumour staging and resectability. in this article, we aim to review the physical principles of contrast harmonic imaging</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;CEH-EUS was recently developed to overcome the difficulties experienced with Doppler EUS.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;The past decade has witnessed great activity towards the development of stabilised microbubble contrast agents. During the same time period, there have also been enhancements of the available ultrasound equipment, such as HI-specific software and broad-band transducers, which have dramatically improved the ability of US to explore microcirculation and given rise to the evolution of contrast-enhanced transabdominal US for uses ranging from vascular imaging to images of the perfused tissue. Additionally, endoscopic ultrasonography (EUS) has become the imaging modality with the highest spatial resolution since its introduction in the 1980s. However, because of its low acoustic power and limited bandwidth, contrast-enhanced harmonic endoscopic ultrasound (CHEUS) has not been feasible until five years ago, when technological advances made contrast harmonic technology available for the first time for EUS. Although experience is still limited, several reports have highlighted this technique as a promising noninvasive method, not only for characterising lesions but also for better assessing tumour staging and resectability. In this article, we aim to review the physical principles of contrast harmonic imaging&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Overcoming Doppler’s problem by suppression the background tissue signals
Harmonic imaging (HI) specific software
dCHI in Hitachi
ExPHD mode in ALOKA system
Broad-band transducers
From vascular imaging to images of the perfused tissue
First report in 2008 by Kitano M et al. (J Med Ultrasonics)
Preliminary study of CEH-EUS with 2nd generation UCAs

Contrast-enhanced harmonic EUS
Dietrich CF et al. Z Gastroenterol (2005)
Kitano M et al. Gastrointest Endosc (2008)</text>
		</slide>
		<slide index="13" title="Basic principle of CEH-EUS" titleNormalized="basic principle of ceh-eus" src="slide14.swf" size="2317" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="41.9080004"/>
			</animationSteps>
			<notes>The first experience with CH-EUS using a new linear prototype echoendoscope was reported by Kitano et al. Initially, they carried out experiments in vitro on a phantom model to determine the optimal MI. The maximum changes in echointensity were observed with a MI of 0.35-0.40. Then, they performed in vivo experiments on dogs to examine the microcirculation of the canine digestive organs and, finally, on two patients, one with pancreatic cancer and another with a gastrointestinal stromal tumour. CH-EUS showed no vessels in the pancreatic tumour, although diffuse fine vessels were detected inside the stromal tumour. These results suggest the possible role of CH-EUS in the investigation of certain pathological digestive conditions.</notes>
			<notesNormalized>the first experience with ch-eus using a new linear prototype echoendoscope was reported by kitano et al. initially, they carried out experiments in vitro on a phantom model to determine the optimal mi. the maximum changes in echointensity were observed with a mi of 0.35-0.40. then, they performed in vivo experiments on dogs to examine the microcirculation of the canine digestive organs and, finally, on two patients, one with pancreatic cancer and another with a gastrointestinal stromal tumour. ch-eus showed no vessels in the pancreatic tumour, although diffuse fine vessels were detected inside the stromal tumour. these results suggest the possible role of ch-eus in the investigation of certain pathological digestive conditions.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="10"&gt;The first experience with CH-EUS using a new linear prototype echoendoscope was reported by Kitano &lt;i&gt;et al&lt;/i&gt;. Initially, they carried out experiments &lt;i&gt;in vitro &lt;/i&gt;on a phantom model to determine the optimal MI. The maximum changes in echointensity were observed with a MI of 0.35-0.40. Then, they performed &lt;i&gt;in vivo &lt;/i&gt;experiments on dogs to examine the microcirculation of the canine digestive organs and, finally, on two patients, one with pancreatic cancer and another with a gastrointestinal stromal tumour. CH-EUS showed no vessels in the pancreatic tumour, although diffuse fine vessels were detected inside the stromal tumour. These results suggest the possible role of CH-EUS in the investigation of certain pathological digestive conditions.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Basic principle of CEH-EUS
Access of large vessel
16-18G IV catheter
Three-way stop-cock
Slow infusion of UCA followed by a saline flush
Dual screen display
Conventional B-mode and ExPHD mode
Lower mechanical index (below 0.4)
Lower MI (0.25-0.30) for the lesion near the transducer (&lt; 2 cm)
Higher MI (0.35-0.40) for the lesion away form the transducer (1.5-3.0 cm)
Observation of enhancement pattern during
Arterial phase (first 30-35 secs)
Venous phase (30-120 secs)
</text>
		</slide>
		<slide index="14" title="Contrast-enhanced harmonic EUS" titleNormalized="contrast-enhanced harmonic eus" src="slide15.swf" size="199319" advanceOnTime="1" framesCount="1899" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="1898" playTime="44.1800003" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Conventional B-mode
Dual mode (B-mode and ExPHD mode)
Contrast-enhanced harmonic EUS
Parameters
- Degree of enhancement: no-, hypo-, iso-, and hyperenhancement
- Phase: microvessels (arterial phase) and perfusion (venous phase)</text>
		</slide>
		<slide index="15" title="Comparison of CH-EUS between normal pancreas and pancreatic cancer" titleNormalized="comparison of ch-eus between normal pancreas and pancreatic cancer" src="slide16.swf" size="321005" advanceOnTime="1" framesCount="2575" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video5" videoClipId="ispring.resources_1d306110.spr0_15196416" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d306110.spr2_15196416" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video6" videoClipId="ispring.resources_1d306110.spr0_15222889" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d306110.spr2_15222889" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video5" startPos="0.0000000"/>
				<playVideo frameIndex="0" videoId="video6" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="2574" playTime="24.4899998" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Comparison of CH-EUS between normal pancreas and pancreatic cancer</text>
		</slide>
		<slide index="16" title="Clinical applications of UCAs in EUS" titleNormalized="clinical applications of ucas in eus" src="slide17.swf" size="1887" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="18.7510008"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Clinical applications of UCAs in EUS
Contrast-enhanced EUS (CE-EUS)
Color and/or power Doppler imaging
1st and 2nd generation UCAs
Contrast-enhanced harmonic EUS (CH-EUS)
2nd generation UCAs
</text>
		</slide>
		<slide index="17" title="Clinical applications" titleNormalized="clinical applications" src="slide18.swf" size="1857" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="21.9880003"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Clinical applications
Solid pancreatic mass
Cystic pancreatic neoplasm
Gastrointestinal stromal tumors
Lymphadenopathies
Others
Gallbladder polyp
Biliary tract diseases</text>
		</slide>
		<slide index="18" title="EUS using UCAs in pancreatic solid lesions" titleNormalized="eus using ucas in pancreatic solid lesions" src="slide19.swf" size="2412" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset18" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="28.2609991"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS using UCAs in pancreatic solid lesions
Differentiation between pancreatic AC and other pancreatic pathologies
Four types of enhancement pattern
Non-, hypo-, iso- and hyper-enhancement
Two phases
Arterial and venous
Overall diagnostic performances
Sensitivity of 94% (95% CI: 0.91-.095)
Specificity of 89% (95% CI: 0.85-0.92)
Higher accuracy in diagnosing small pancreatic cancer (&lt; 2cm) comparing MDCT
Sensitivity of 91.2%
Specificity of 94.4% 
Kitano M et al. Am J Gastronenterol (2012)
Gong TT et al. Gastrointest Endosc (2012)</text>
		</slide>
		<slide index="19" title="Case of pancreatic ductal adenocarcinoma" titleNormalized="case of pancreatic ductal adenocarcinoma" src="slide20.swf" size="292414" advanceOnTime="1" framesCount="1096" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset19" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video7" videoClipId="ispring.resources_1d3065f0.spr0_15234059" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d3065f0.spr2_15234059" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video7" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="1095" playTime="20.7199993" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>1159963</notes>
			<notesNormalized>1159963</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;1159963&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case of pancreatic ductal adenocarcinoma</text>
		</slide>
		<slide index="20" title="Case of pancreatic ductal adenocarcinoma" titleNormalized="case of pancreatic ductal adenocarcinoma" src="slide21.swf" size="357229" advanceOnTime="1" framesCount="2575" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset20" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video8" videoClipId="ispring.resources_1d58d2b0.spr0_15271873" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d58d2b0.spr2_15271873" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video8" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="2574" playTime="32.2999992" pauseTime="0.0000000"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Case of pancreatic ductal adenocarcinoma</text>
		</slide>
		<slide index="21" title="Diagnostic performances of CE-EUS and CH-EUS" titleNormalized="diagnostic performances of ce-eus and ch-eus" src="slide22.swf" size="7961" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset21" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="16.0789999"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Modified from Fusaroli P et al. Gastrointest Endosc (2016)
Diagnostic performances of CE-EUS and CH-EUS
Authors (year)
Design
Technique
UCA
Cases
Sensitivity (%)
Specificity (%)
Accuracy (%)
Figueiredo et al (2012)
PS
CE-EUS+E
SonoVue
47
93
67
79
Săftoiu et al (2010)
PS
CE-EUS+E
SonoVue
54
88
100
93
Sakamoto et al (2008)
PS
CE-EUS
Levovist
156
85
89
87
Dietrich et al (2008)
PS
CE-EUS
Levovist
93
92
100
95
Hocke et al (2007)
RS
CE-EUS
SonoVue
100
78
87
NR
Hocke et al (2006)
PS
CE-EUS
SonoVue
86
91
93
NR
Becker et al (2001)
PS
CE-EUS
Optison
23
94
100
NR
Total, mean (range)
559
89 (78-94)
91 (67-100)
89 (79-95)
Gincul et al (2014)
PS-M
CH-EUS
SonoVue
100
96
94
95
Park et al (2014)
RS
CH-EUS
SonoVue
90
92
68
84
Lee et al (2013)
PS
CH-EUS
SonoVue
37
93
86
92
Hocke et al (2012)
PS
CH-EUS
SonoVue
58
92
90
NR
Kitano et al ( 2012)
PS
CH-EUS
Sonazoid
277
95
89
91
Fusaroli et al (2010)
PS
CH-EUS
SonoVue
90
96
64
82
Napoleon et al (2010)
PS
CH-EUS
SonoVue
35
89
88
89
Total, mean (range)
687
93 (89-96)
83 (64-94)
89 (82-95)</text>
		</slide>
		<slide index="22" title="EUS using UCAs in pancreatic solid lesions" titleNormalized="eus using ucas in pancreatic solid lesions" src="slide23.swf" size="2495" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset22" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="71.4039988"/>
			</animationSteps>
			<notes>Furthermore, CEH-EUS was also superior in predicting the T-stage of pancreatobiliary tumors as compared with conventional EUS. In particular by CEH-EUS, the wall of the portal vein was better depicted, enabling better visualization of portal vein invasion and providing valuable information for surgical planning for vascular resection. In patients with unresectable carcinoma of the pancreas, CEH-EUS has also been demonstrated to aid in predicting efficacy of chemotherapy. The presence of intratumoral vessels predicted a better progression free and overall survival after chemotherapy. On the other hand, a hyper-enhancing pattern was identified to be a common feature in pancreatic neuroendocrine tumors (PNETs), with a sensitivity of 78.9% and a specificity of 98.0%[20] (Figure 3). The presence of filling defects within an enhancing pancreatic lesion corresponded to hemorrhage or necrosis of malignant diseases as seen on pathological examination. This may have a potential role in differentiating benign versus malignant PNETs.</notes>
			<notesNormalized>furthermore, ceh-eus was also superior in predicting the t-stage of pancreatobiliary tumors as compared with conventional eus. in particular by ceh-eus, the wall of the portal vein was better depicted, enabling better visualization of portal vein invasion and providing valuable information for surgical planning for vascular resection. in patients with unresectable carcinoma of the pancreas, ceh-eus has also been demonstrated to aid in predicting efficacy of chemotherapy. the presence of intratumoral vessels predicted a better progression free and overall survival after chemotherapy. on the other hand, a hyper-enhancing pattern was identified to be a common feature in pancreatic neuroendocrine tumors (pnets), with a sensitivity of 78.9% and a specificity of 98.0%[20] (figure 3). the presence of filling defects within an enhancing pancreatic lesion corresponded to hemorrhage or necrosis of malignant diseases as seen on pathological examination. this may have a potential role in differentiating benign versus malignant pnets.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Furthermore, CEH-EUS was also superior in predicting the T-stage of pancreatobiliary tumors as compared with conventional EUS. In particular by CEH-EUS, the wall of the portal vein was better depicted, enabling better visualization of portal vein invasion and providing valuable information for surgical planning for vascular resection. In patients with unresectable carcinoma of the pancreas, CEH-EUS has also been demonstrated to aid in predicting efficacy of chemotherapy. The presence of intratumoral vessels predicted a better progression free and overall survival after chemotherapy. On the other hand, a hyper-enhancing pattern was identified to be a common feature in pancreatic neuroendocrine tumors (PNETs), with a sensitivity of 78.9% and a specificity of 98.0%[20] (Figure 3). The presence of filling defects within an enhancing pancreatic lesion corresponded to hemorrhage or necrosis of malignant diseases as seen on pathological examination. This may have a potential role in differentiating benign versus malignant PNETs.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS using UCAs in pancreatic solid lesions
Superior in predicting T stage of pancreatobiliary tumors comparing conventional EUS
Better visualization of portal vein wall
Prediction of efficacy of chemotherapy in unresectable pancreatic carcinoma
Better survival in the presence of intratumoral vessels
Differentiation of benign versus malignant pNET
Hyper-enhancing pattern
Sensitivity of 78.9% and specificity of 98%
Present of filling defect within enhancing pancreatic lesion
Hemorrhage or necrosis of malignancy
Imazu H. et al Scand J Gastronenterol (2010)
Yamashita Y et al. Pancreas (2013)
Ishikawa T et al. Gastrointest Endosc (2010)</text>
		</slide>
		<slide index="23" title="Case of pancreatic NET" titleNormalized="case of pancreatic net" src="slide24.swf" size="322661" advanceOnTime="1" framesCount="1367" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset23" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video9" videoClipId="ispring.resources_1d58c1a0.spr0_15275399" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d58c1a0.spr2_15275399" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video10" videoClipId="ispring.resources_1d9e5140.spr0_15275602" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d9e5140.spr2_15275602" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video11" videoClipId="ispring.resources_1d9e5140.spr0_15285851" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d9e5140.spr2_15285851" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video12" videoClipId="ispring.resources_1d9e53b0.spr0_15292185" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d9e53b0.spr2_15292185" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="290" videoId="video9" startPos="0.0000000"/>
				<playVideo frameIndex="654" videoId="video11" startPos="0.0000000"/>
				<playVideo frameIndex="410" videoId="video12" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="1366" playTime="32.8699989" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>7020721</notes>
			<notesNormalized>7020721</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;7020721&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case of pancreatic NET</text>
		</slide>
		<slide index="24" title="Interobserver agreement in CH-EUS" titleNormalized="interobserver agreement in ch-eus" src="slide25.swf" size="2642" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset24" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="46.0120005"/>
			</animationSteps>
			<notes>However, inter-observer agreement of CEH-EUS was only found to be fair to moderate. Upon a review of 80 EUS videos by 15 endosonographers, overall inter-observer agreement was moderate for the uptake of contrast agents (k = 0.567) and fair for the pattern of distribution (k = 0.304) and the washout velocity (k = 0.369). This finding highlighted a major limitation of the technique that qualitative image
analysis of contrast enhanced images is subjected to individual interpretation.</notes>
			<notesNormalized>however, inter-observer agreement of ceh-eus was only found to be fair to moderate. upon a review of 80 eus videos by 15 endosonographers, overall inter-observer agreement was moderate for the uptake of contrast agents (k = 0.567) and fair for the pattern of distribution (k = 0.304) and the washout velocity (k = 0.369). this finding highlighted a major limitation of the technique that qualitative image
analysis of contrast enhanced images is subjected to individual interpretation.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;However, inter-observer agreement of CEH-EUS was only found to be fair to moderate. Upon a review of 80 EUS videos by 15 endosonographers, overall inter-observer agreement was moderate for the uptake of contrast agents (&lt;i&gt;k &lt;/i&gt;= 0.567) and fair for the pattern of distribution (&lt;i&gt;k &lt;/i&gt;= 0.304) and the washout velocity (&lt;i&gt;k &lt;/i&gt;= 0.369). This finding highlighted a major limitation of the technique that qualitative image&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;analysis of contrast enhanced images is subjected to individual interpretation.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Interobserver agreement in CH-EUS
IOA for the assessment of pancreatic solid neoplasms
Overall IOA in solid pancreatic lesions
Moderate for the uptake of UCAs (k=0.567)
Fair for the pattern of distribution (k=0.304) and washout velocity (k=0.369)
Between senior and junior operator
Good for all operator (k=0.66)
Good for the junior (k=0.76)
Excellent for the senior (k=0.90)
According to experience
Better IOA of experienced operator in EUS and CH-EUS
Fair for overall IOA (k=0.32)

Fusaroli P et al. J Gastroenterol Hepatol (2012)
Gincul R et al. Endoscopy (2014)
Soares JB et al. Endosc Int Open (2015)</text>
		</slide>
		<slide index="25" title="Quantitative analysis of CE-EUS" titleNormalized="quantitative analysis of ce-eus" src="slide26.swf" size="1674" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset25" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="31.9980005"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Quantitative analysis of CE-EUS
Analysis of TIC (time intensity curve)
Image Pro Plus
Histogram
Vuebox software</text>
		</slide>
		<slide index="26" title="Saftoiu et al. GIE (2015)" titleNormalized="saftoiu et al. gie (2015)" src="slide27.swf" size="202828" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset26" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="8.6790003"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Saftoiu et al. GIE (2015)
Gheonea et al BMC gastroenterol (2013)
Imazu et al. Scand J Gastroenterol (2012)
Seicean et al. Ultraschall Med (2010)</text>
		</slide>
		<slide index="27" title="Diagnostic performances of quantitative CH-EUS" titleNormalized="diagnostic performances of quantitative ch-eus" src="slide28.swf" size="4640" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset27" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="21.4889998"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Authors (year)
Design
Quantitative analysis
UCA
Cases
Sensitivity (%)
Specificity (%)
Accuracy (%)
Săftoiu et al (2015)
PS-M
Vuebox and ANN
SonoVue
167
88
93
NR
Gheonea et al (2013)
PS
Image Pro Plus
SonoVue
51
94
89
NR
Imazu et al (2012)
PS
TIC analysis in ALOKA
Sonazoid
30
100
100
NR
Matsubara et al (2011)
RS
TIC analysis
Sonazoid
91
96
93
95
Seicean et al (2010)
PS
Histogram analysis
SonoVue
30
80
92
86
Total, mean (range)
369
92 (80-100)
93 (89-100)
91 (86-95) 
Modified from Fusaroli P et al. Gastrointest Endosc (2016)
Diagnostic performances of quantitative CH-EUS</text>
		</slide>
		<slide index="28" title="" titleNormalized="" src="slide29.swf" size="1056387" advanceOnTime="1" framesCount="979" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset28" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="978" playTime="40.7500000" pauseTime="21.6790009"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
		</slide>
		<slide index="29" title="Vuebox analyzing software and its parameters" titleNormalized="vuebox analyzing software and its parameters" src="slide30.swf" size="106856" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset29" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="11.9389996"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Vuebox analyzing software and its parameters</text>
		</slide>
		<slide index="30" title="" titleNormalized="" src="slide31.swf" size="410296" advanceOnTime="1" framesCount="579" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset30" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="578" playTime="24.0833333" pauseTime="4.3116671"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
		</slide>
		<slide index="31" title="" titleNormalized="" src="slide32.swf" size="9677" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset31" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="11.6770005"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Authors (year)
Design
Technique
UCA
Cases
Sensitivity (%)
Specificity (%)
Accuracy (%)
Figueiredo et al (2012)
PS
CE-EUS+E
SonoVue
47
93
67
79
Săftoiu et al (2010)
PS
CE-EUS+E
SonoVue
54
88
100
93
Sakamoto et al (2008)
PS
CE-EUS
Levovist
156
85
89
87
Dietrich et al (2008)
PS
CE-EUS
Levovist
93
92
100
95
Hocke et al (2007)
RS
CE-EUS
SonoVue
100
78
87
NR
Hocke et al (2006)
PS
CE-EUS
SonoVue
86
91
93
NR
Becker et al (2001)
PS
CE-EUS
Optison
23
94
100
NR
Total, mean (range)
559
89 (78-94)
91 (67-100)
89 (79-95)
Gincul et al (2014)
PS-M
CH-EUS
SonoVue
100
96
94
95
Park et al (2014)
RS
CH-EUS
SonoVue
90
92
68
84
Lee et al (2013)
PS
CH-EUS
SonoVue
37
93
86
92
Hocke et al (2012)
PS
CH-EUS
SonoVue
58
92
90
NR
Kitano et al ( 2012)
PS
CH-EUS
Sonazoid
277
95
89
91
Fusaroli et al (2010)
PS
CH-EUS
SonoVue
90
96
64
82
Napoleon et al (2010)
PS
CH-EUS
SonoVue
35
89
88
89
Total, mean (range)
687
93 (89-96)
83 (64-94)
89 (82-95)
Săftoiu et al (2015)
PS-M
qCH-EUS
SonoVue
167
88
93
NR
Gheonea et al (2013)
PS
qCH-EUS
SonoVue
51
94
89
NR
Imazu et al (2012)
PS
qCH-EUS
Sonazoid
30
100
100
NR
Matsubara et al (2011)
RS
qCH-EUS
Sonazoid
91
96
93
95
Seicean et al (2010)
PS
qCH-EUS
SonoVue
30
80
92
86
Total, mean (range)
369
92 (80-100)
93 (89-100)
91 (86-95)</text>
		</slide>
		<slide index="32" title="Pancreatic cystic lesions" titleNormalized="pancreatic cystic lesions" src="slide33.swf" size="2474" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset32" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="7.4060001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Pancreatic cystic lesions
Cytopathologic analysis of EUS-FNA samples
Definitive diagnosis in only 50% of cases
Presence of enhancing solid component/mural nodule within cyst
Strong predictor of malignancy
Suboptimal accuracy of EUS-FNA due to high false-negative rate
CH-EUS
Good differentiation between pseudocyst and cystic neoplasms
Observing enhancement of cystic wall or intracystic lesions (septae, nodules)
Impossible differentiation among PCNs
Role in the differentiation of mural nodule and mucin plug (?)
Hocke M et al. Endosc Ultrasound (2014)
Fusaroli P et al. Panceas (2016)
Kamata K et al. Endoscopy (2016)</text>
		</slide>
		<slide index="33" title="Take home messages" titleNormalized="take home messages" src="slide34.swf" size="2035" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset33" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="25.6249995"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Take home messages
Contrast-enhanced EUS
Good imaging modality in the diagnosis of pancreatic ductal adenocarcinoma
Differentiation between pseudocyst and PCNs
Standardization of imaging analysis protocol
Quantitative analysis
Limitations
Differentiation among non malignant pancreatic lesions
Differentiation among PCNs</text>
		</slide>
		<slide index="34" title="Thank you for your attention." titleNormalized="thank you for your attention." src="slide35.swf" size="1508" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset34" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="4.0700001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>2016-09-09 Session 3. Advances in Diagnosis and Management of Solid Pancreatic Tumor
Thank you for your attention.</text>
		</slide>
	</slides>
</presentation>
